Strategic collaboration focused on solid-dosage highly potent APIs6 September 2010
BUBENDORF, Switzerland (Sept 6, 2010) — CARBOGEN AMCIS AG, a Switzerland-based pharmaceutical process development and active pharmaceutical ingredient (
“Due to the improved side-effect profiles of many new classes of highly potent
The strategic alliance with CARBOGEN AMCIS will encompass integrated services, spanning from high-potency
CARBOGEN AMCIS’ offerings include categorization and OEL assessment, process research and development, analytical-method development and validation, manufacturing of
EirGen’s offerings include formulation development, excipient-compatibility studies, specification development, pre-clinical supplies, clinical supplies and exhibit-batch manufacturing, assay and dissolution-method development as well as validation, degradation studies, cleaning verification, oral solid-dose manufacturing and packaging (tablets, capsules, bottles and blisters).
“The partnership will result in reduced time to market for our customers’ highly potent drug products through streamlined project management” added Patsy Carney, managing director of EirGen Pharma. “We’re delighted to work with CARBOGEN AMCIS, particularly as they offer our customers alternative sites for highly potent
CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.
EirGen Pharma Ltd (www.eirgen.com) is a pharmaceutical company based in Waterford, Ireland specialised in the development, registration and manufacture of high potency solid-dose products for global markets. EirGen Pharma offers a unique range of pharmaceutical development services for new active substances, generics and upgrades of existing formulations.
Source: CARBOGEN AMCIS AG, Bubendorf, Switzerland